This biotech innovator in antibody therapies just reported a significant insider sale amid a period of strong share price ...
On Thursday, Eli Lilly and Co. (NYSE:LLY) revealed topline results from the novel TOGETHER-PsA open-label Phase 3b trial ...
One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for ...
The clinical-stage biotech could see its shares plummet should there be any clinical setback.
A new study has found that people who use weight loss drugs tend to regain the weight rapidly after stopping, and faster than ...
Users swear by kratom for lifting mood and boosting energy, but there are many safety issues and questions about ...
MapLight Therapeutics, Inc. (“MapLight”) (Nasdaq: MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ML-007C-MA, an investigational novel ...
Amazon Pharmacy maintains the requirement for a valid prescription as the central safeguard separating evidence-based medical ...
Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026Full imaging and ...
The NHS has issued an important notice to patients taking Mounjaro weight loss injections alongside the contraceptive pill or ...
19h
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
NEWARK, CA / ACCESS Newswire / January 7, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today ...
Integration of prescription drug dispensing optimization aritifical intelligence platform EinsteinRx™ into pharmacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback